Mesenchymal stem cells as immunomodulators in a vascularized composite allotransplantation

Yur Ren Kuo*, Chien Chang Chen, Shigeru Goto, Pao Yuan Lin, Fu Chan Wei, Chao Long Chen

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

30 Scopus citations


Vascularized composite allotransplantations (VCAs) are not routinely performed for tissue reconstruction because of the potentially harmful adverse effects associated with lifelong administration of immunosuppressive agents. Researchers have been eagerly seeking alternative methods that circumvent the long-term use of immunosuppressants. Mesenchymal stem cells (MSCs) show promise as an immunomodulatory therapeutic agent and are currently being tested in preclinical and clinical settings as therapies for autoimmune disorders or transplant rejection. The mechanisms by which MSCs modulate the immune response are still under thorough investigation, but these most likely involve expression of local factors influencing T-cell regulation, modulation of cytokine expression (e.g., IL-10, TGF-β, TNF-α, INF-γ, etc.), and interactions with dendritic or antigen presenting cells. In this paper, we summarize the current understanding of immunomodulation achieved by MSC therapies and introduce a possible outline for future clinical applications in VCA.

Original languageEnglish
Article number854846
JournalClinical and Developmental Immunology
StatePublished - 2012


Dive into the research topics of 'Mesenchymal stem cells as immunomodulators in a vascularized composite allotransplantation'. Together they form a unique fingerprint.

Cite this